{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T10:11:05Z","timestamp":1790676665842,"version":"4.1.0"},"reference-count":90,"publisher":"MDPI AG","issue":"20","license":[{"start":{"date-parts":[[2020,10,11]],"date-time":"2020-10-11T00:00:00Z","timestamp":1602374400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Generally, dementia should be considered an acquired syndrome, with multiple possible causes, rather than a specific disease in itself. The leading causes of dementia are neurodegenerative and non-neurodegenerative alterations. Nevertheless, the neurodegenerative group of diseases that lead to cognitive impairment and dementia includes multiple possibilities or mixed pathologies with personalized treatment management for each cause, even if Alzheimer\u2019s disease is the most common pathology. Therefore, an accurate differential diagnosis is mandatory in order to select the most appropriate therapy approach. The role of personalized assessment in the treatment of dementia is rapidly growing. Neuroimaging is an essential tool for differential diagnosis of multiple causes of dementia and allows a personalized diagnostic and therapeutic protocol based on risk factors that may improve treatment management, especially in early diagnosis during the prodromal stage. The utility of structural and functional imaging could be increased by standardization of acquisition and analysis methods and by the development of algorithms for automated assessment. The aim of this review is to focus on the most commonly used tracers for differential diagnosis in the dementia field. Particularly, we aim to explore 18F Fluorodeoxyglucose (FDG) and amyloid positron emission tomography (PET) imaging in Alzheimer\u2019s disease and in other neurodegenerative causes of dementia.<\/jats:p>","DOI":"10.3390\/ijms21207481","type":"journal-article","created":{"date-parts":[[2020,10,13]],"date-time":"2020-10-13T22:02:02Z","timestamp":1602626522000},"page":"7481","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Positron Emission Tomography (PET) and Neuroimaging in the Personalized Approach to Neurodegenerative Causes of Dementia"],"prefix":"10.3390","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9277-6337","authenticated-orcid":false,"given":"Maria","family":"Ricci","sequence":"first","affiliation":[{"name":"Department of Biomedicine and Prevention, University of Rome Tor Vergata, 00133 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0533-2947","authenticated-orcid":false,"given":"Andrea","family":"Cimini","sequence":"additional","affiliation":[{"name":"Department of Biomedicine and Prevention, University of Rome Tor Vergata, 00133 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agostino","family":"Chiaravalloti","sequence":"additional","affiliation":[{"name":"Department of Biomedicine and Prevention, University of Rome Tor Vergata, 00133 Rome, Italy"},{"name":"Nuclear Medicine Section, IRCCS Neuromed, 86077 Pozzilli, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4423-5496","authenticated-orcid":false,"given":"Luca","family":"Filippi","sequence":"additional","affiliation":[{"name":"Nuclear Medicine Section, \u201cSanta Maria Goretti\u201d Hospital, 04100 Latina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orazio","family":"Schillaci","sequence":"additional","affiliation":[{"name":"Department of Biomedicine and Prevention, University of Rome Tor Vergata, 00133 Rome, Italy"},{"name":"Nuclear Medicine Section, IRCCS Neuromed, 86077 Pozzilli, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,10,11]]},"reference":[{"key":"ref_1","first-page":"963","article-title":"The global prevalence of dementia: A systematic review and metaanalysis","volume":"56","author":"Prince","year":"2013","journal-title":"Alzheimers Dement."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1016\/j.amjmed.2018.01.022","article-title":"Dementia","volume":"131","author":"Gale","year":"2018","journal-title":"Am. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1212\/WNL.0b013e31828726f5","article-title":"Alzheimer disease in the United States (2010\u20132050) estimated using the 2010 census","volume":"7","author":"Hebert","year":"2013","journal-title":"Neurology"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.jalz.2016.02.002","article-title":"Preclinical Alzheimer\u2019s disease: Definition, natural history, and diagnostic criteria","volume":"12","author":"Dubois","year":"2016","journal-title":"Alzheimers Dement."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/BF00308809","article-title":"Neuropathological stageing of Alzheimer-related changes","volume":"82","author":"Braak","year":"1991","journal-title":"Acta Neuropathol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/nrneurol.2009.215","article-title":"The clinical use of structural MRI in Alzheimer disease","volume":"6","author":"Frisoni","year":"2010","journal-title":"Nat. Rev. Neurol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.neuroimage.2017.03.057","article-title":"A review on neuroimaging-based classification studies and associated feature extraction methods for Alzheimer\u2019s disease and its prodromal stages","volume":"15","author":"Rathore","year":"2017","journal-title":"Neuroimage"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"843","DOI":"10.3233\/JAD-2010-091504","article-title":"Pre-clinical detection of Alzheimer\u2019s disease using FDG-PET, with or without amyloid imaging","volume":"20","author":"Mosconi","year":"2010","journal-title":"J. Alzheimers Dis."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/j.nicl.2018.03.007","article-title":"Development and validation of a novel dementia of Alzheimer\u2019s type (DAT) score based on metabolism FDG-PET imaging","volume":"10","author":"Popuri","year":"2018","journal-title":"Neuroimage Clin."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.nicl.2014.11.007","article-title":"Volume of interest-based 18Ffluorodeoxyglucose PET discriminates MCI converting to Alzheimer\u2019s disease from healthy controls. A European Alzheimer\u2019s Disease Consortium (EADC) study","volume":"7","author":"Pagani","year":"2014","journal-title":"Neuroimage Clin."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.ncl.2017.01.005","article-title":"Early-Onset Alzheimer Disease","volume":"35","author":"Mendez","year":"2017","journal-title":"Neurol. Clin."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1159\/000441776","article-title":"Comparison between Early-Onset and Late-Onset Alzheimer\u2019s Disease Patients with Amnestic Presentation: CSF and (18)F-FDG PET Study","volume":"6","author":"Chiaravalloti","year":"2016","journal-title":"Dement. Geriatr. Cogn. Dis. Extra"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1111\/ene.13728","article-title":"European Association of Nuclear Medicine and European Academy of Neurology recommendations for the use of brain 18 F-fluorodeoxyglucose positron emission tomography in neurodegenerative cognitive impairment and dementia: Delphi consensus","volume":"25","author":"Nobili","year":"2018","journal-title":"Eur. J. Neurol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1007\/s12149-020-01441-2","article-title":"The role of epsilon phenotype in brain glucose consumption in Alzheimer\u2019s disease","volume":"34","author":"Ricci","year":"2020","journal-title":"Ann. Nucl. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.3233\/JAD-191046","article-title":"Neuroimaging in Vascular Cognitive Impairment and Dementia: A Systematic Review","volume":"73","author":"Frantellizzi","year":"2020","journal-title":"J. Alzheimers Dis."},{"key":"ref_16","first-page":"11","article-title":"Evaluation of therapeutic response to donepezil by positron emission tomography","volume":"57","author":"Shimada","year":"2011","journal-title":"Osaka City Med. J."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1001\/archneur.62.5.721","article-title":"Metabolic patterns associated with the clinical response to galantamine therapy: A fludeoxyglucose f 18 positron emission tomographic study","volume":"62","author":"Mega","year":"2005","journal-title":"Arch. Neurol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1097\/JCP.0b013e31829a876a","article-title":"Effects of memantine on clinical ratings, fluorodeoxyglucose positron emission tomography measurements, and cerebrospinal fluid assays in patients with moderate to severe Alzheimer dementia: A 24-week, randomized, clinical trial","volume":"33","author":"Wang","year":"2013","journal-title":"J. Clin. Psychopharmacol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1097\/JGP.0b013e3181ca3a4e","article-title":"Effect of memantine treatment on regional cortical metabolism in Alzheimer\u2019s disease","volume":"18","author":"Sultzer","year":"2010","journal-title":"Am. J. Geriatr. Psychiatr."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.ejrad.2017.07.014","article-title":"The diagnostic value of FDG and amyloid PET in Alzheimer\u2019s disease-A systematic review","volume":"94","author":"Rice","year":"2017","journal-title":"Eur. J. Radiol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1002\/ana.20009","article-title":"Imaging brain amyloid in Alzheimer\u2019s disease with Pittsburgh Compound-B","volume":"55","author":"Klunk","year":"2004","journal-title":"Ann. Neurol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.2967\/jnumed.110.076315","article-title":"Brain amyloid imaging","volume":"52","author":"Rowe","year":"2011","journal-title":"J. Nucl. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S1474-4422(08)70001-2","article-title":"Imaging of amyloid beta in Alzheimer\u2019s disease with 18F-BAY94-9172, a novel PET tracer: Proof of mechanism","volume":"7","author":"Rowe","year":"2008","journal-title":"Lancet Neurol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1007\/s40263-015-0258-7","article-title":"[(18)F]Florbetaben: A review in \u03b2-amyloid PET imaging in cognitive impairment","volume":"29","author":"Syed","year":"2015","journal-title":"CNS Drugs"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s40336-015-0102-6","article-title":"Beta-amyloid imaging with florbetaben","volume":"3","author":"Sabri","year":"2015","journal-title":"Clin. Transl. Imaging"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.nucmedbio.2005.06.001","article-title":"F-18 Polyethyleneglycol stilbenes as PET imaging agents targeting Abeta aggregates in the brain","volume":"32","author":"Zhang","year":"2005","journal-title":"Nucl. Med. Biol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1016\/j.jalz.2015.02.004","article-title":"Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer\u2019s disease: Phase 3 study. 1","volume":"11","author":"Sabri","year":"2015","journal-title":"Alzheimers Dement."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1093\/brain\/awn016","article-title":"Postmortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer\u2019s disease","volume":"131 Pt 6","author":"Ikonomovic","year":"2008","journal-title":"Brain"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1136\/jnnp-2014-308094","article-title":"A\u03b2 imaging with 18F-florbetaben in prodromal Alzheimer\u2019s disease: A prospective outcome study","volume":"86","author":"Ong","year":"2015","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1212\/WNL.0b013e318212015e","article-title":"Amyloid PET imaging in patients with mild cognitive impairment: A 2-year follow-up study","volume":"76","author":"Koivunen","year":"2011","journal-title":"Neurology"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1056\/NEJMoa1304839","article-title":"Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer\u2019s disease","volume":"370","author":"Salloway","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/nature19323","article-title":"The antibody aducanumab reduces A\u03b2 plaques in Alzheimer\u2019s disease","volume":"537","author":"Sevigny","year":"2016","journal-title":"Nature"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s13195-018-0424-5","article-title":"Amyloid positron emission tomography and cerebrospinal fluid results from a crenezumab anti-amyloid-beta antibody double-blind, placebo-controlled, randomized phase II study in mild-to-moderate Alzheimer\u2019s disease (BLAZE)","volume":"10","author":"Salloway","year":"2018","journal-title":"Alzheimers Res. Ther."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s13195-017-0318-y","article-title":"A phase III randomized trial of gantenerumab in prodromal Alzheimer\u2019s disease","volume":"9","author":"Ostrowitzki","year":"2017","journal-title":"Alzheimers Res Ther."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1056\/NEJMoa1812840","article-title":"Randomized Trial of Verubecestat for Prodromal Alzheimer\u2019s Disease","volume":"380","author":"Egan","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1001\/jamaneurol.2014.2031","article-title":"Synergistic effect of \u03b2-amyloid and neurodegeneration on cognitive decline in clinically normal individuals","volume":"71","author":"Mormino","year":"2014","journal-title":"JAMA Neurol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1007\/s00259-016-3353-1","article-title":"Early [(18)F]florbetaben and [(11)C]PiB PET images are a surrogate biomarker of neuronal injury in Alzheimer\u2019s disease","volume":"43","author":"Tiepolt","year":"2016","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_38","first-page":"268","article-title":"18 F-labeled radiopharmaceuticals for the molecular neuroimaging of amyloid plaques in Alzheimer\u2019s disease","volume":"8","author":"Filippi","year":"2018","journal-title":"Am. J. Nucl. Med. Mol. Imaging"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.3233\/JAD-180522","article-title":"Dual Time-Point 18FFlorbetaben PET Delivers Dual Biomarker Information in Mild Cognitive Impairment and Alzheimer\u2019s Disease","volume":"66","author":"Florek","year":"2018","journal-title":"J. Alzheimers Dis."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"a023721","DOI":"10.1101\/cshperspect.a023721","article-title":"Tau Positron Emission Tomography Imaging","volume":"9","author":"Kolb","year":"2017","journal-title":"Cold Spring Harb. Perspect Biol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.cpet.2017.02.005","article-title":"Multimodal PET Imaging of Amyloid and Tau Pathology in Alzheimer Disease and Non-Alzheimer Disease Dementias","volume":"12","author":"Xia","year":"2017","journal-title":"PET Clin."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1002\/ana.24546","article-title":"Tau positron emission tomographic imaging in aging and early Alzheimer disease","volume":"79","author":"Johnson","year":"2016","journal-title":"Ann. Neurol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/j.neuron.2016.01.028","article-title":"PET Imaging of Tau Deposition in the Aging Human Brain","volume":"89","author":"Scholl","year":"2016","journal-title":"Neuron"},{"key":"ref_44","first-page":"157","article-title":"Anti-Tau Trials for Alzheimer\u2019s Disease: A Report from the EU\/US\/CTAD Task Force","volume":"6","author":"Cummings","year":"2019","journal-title":"J. Prev. Alz. Dis."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/S1474-4422(14)70252-2","article-title":"Tau imaging: Early progress and future directions","volume":"14","author":"Villemagne","year":"2015","journal-title":"Lancet Neurol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1177\/2045125317739818","article-title":"Frontotemporal dementia: Latest evidence and clinical implications","volume":"8","author":"Young","year":"2018","journal-title":"Ther. Adv. Psychopharmacol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/nan.12213","article-title":"Invited review: Frontotemporal dementia caused by microtubule-associated protein tau gene (MAPT) mutations: A chameleon for neuropathology and neuroimaging","volume":"41","author":"Ghetti","year":"2015","journal-title":"Neuropathol. Appl. Neurobiol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1136\/jnnp-2012-302577","article-title":"Differentiation of frontotemporal dementia from dementia with Lewy bodies using FP-CIT SPECT","volume":"83","author":"Morgan","year":"2012","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1097\/WNN.0b013e3181864a09","article-title":"Frontotemporal dementia mimicking dementia with Lewy bodies","volume":"21","author":"Claassen","year":"2008","journal-title":"Cogn. Behav. Neurol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"415","DOI":"10.2147\/NDT.S22635","article-title":"Open-label study of the short-term effects of memantine on FDG-PET in frontotemporal dementia","volume":"7","author":"Chow","year":"2011","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.2967\/jnumed.111.089730","article-title":"Amyloid imaging with (18)F-florbetaben in Alzheimer disease and other dementias","volume":"52","author":"Villemagne","year":"2011","journal-title":"J. Nucl. Med."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1007\/s00259-007-0523-1","article-title":"In vivo amyloid imaging with PET in frontotemporal dementia","volume":"35","author":"Engler","year":"2008","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"e-1-16","DOI":"10.1016\/j.jalz.2013.01.002","article-title":"Appropriate use criteria for amyloid PET: A report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer\u2019s Association","volume":"9","author":"Johnson","year":"2013","journal-title":"Alzheimers Dement"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1212\/01.WNL.0000140290.80962.BF","article-title":"Progressive posterior cortical dysfunction: A clinicopathologic series","volume":"63","author":"Renner","year":"2004","journal-title":"Neurology"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1002\/ana.21388","article-title":"Alzheimer and frontotemporal pathology in subsets of primary progressive aphasia","volume":"63","author":"Merusalam","year":"2008","journal-title":"Ann. Neurol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1016\/j.jalz.2016.01.003","article-title":"Characterization of tau positron emission tomography tracer [18 F]AV-1451 binding to postmortem tissue in Alzheimer\u2019s disease, primary tauopathies, and other dementias","volume":"12","author":"Sander","year":"2016","journal-title":"Alzheimers Dement"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1212\/WNL.0000000000004058","article-title":"diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium","volume":"89","author":"McKeith","year":"2017","journal-title":"Neurology"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00415-018-8892-x","article-title":"Neuroimaging in Lewy body dementia","volume":"266","author":"Yousaf","year":"2019","journal-title":"J. Neurol."},{"key":"ref_59","first-page":"215","article-title":"Functional neuroimaging in the diagnosis of patients with Parkinsonism: Update and recommendations for clinical use","volume":"33","author":"Arbizu","year":"2014","journal-title":"Rev. Esp. Med. Nucl. Imagen Mol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.autneu.2017.10.007","article-title":"Diagnosis of multiple system atrophy","volume":"211","author":"Palma","year":"2018","journal-title":"Auton. Neurosci."},{"key":"ref_61","first-page":"CD010633","article-title":"Dopamine transporter imaging for the diagnosis of dementia with Lewy bodies","volume":"1","author":"McCleery","year":"2015","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/S1474-4422(07)70057-1","article-title":"Sensitivity and specificity of dopamine transporter imaging with 123I-FP-CIT SPECT in dementia with Lewy bodies: A phase III, multicentre study","volume":"6","author":"McKeith","year":"2007","journal-title":"Lancet Neurol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1007\/s00415-017-8500-5","article-title":"Deciphering the causes of sporadic late-onset cerebellar ataxias: A prospective study with implications for diagnostic work","volume":"264","author":"Gebus","year":"2017","journal-title":"J. Neurol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1002\/mds.22413","article-title":"Proposed neuroimaging criteria for the diagnosis of multiple system atrophy","volume":"24","author":"Brooks","year":"2009","journal-title":"Mov. Disord."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1002\/cphy.c130026","article-title":"Dysautonomia in Parkinson disease","volume":"4","author":"Goldstein","year":"2014","journal-title":"Compr. Physiol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1002\/mds.23338","article-title":"Abnormal cardiac [(123)I]-meta-iodobenzylguanidine uptake in multiple system atrophy","volume":"25","author":"Nagayama","year":"2010","journal-title":"Mov. Disord."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s40336-018-00309-w","article-title":"Towards consensus in acquisition and image analysis of PET and SPECT in the assessment of cardiac sympathetic innervation: A mini-review","volume":"7","author":"Noordzij","year":"2019","journal-title":"Clin. Transl. Imaging"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S1474-4422(10)70002-8","article-title":"Differential diagnosis of Parkinsonism: A metabolic imaging study using pattern analysis","volume":"9","author":"Tang","year":"2010","journal-title":"Lancet Neurol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"2740","DOI":"10.1093\/brain\/aww193","article-title":"Amyloid-\u03b2 deposition and regional grey matter atrophy rates in dementia with Lewy bodies","volume":"139 Pt 10","author":"Sarro","year":"2016","journal-title":"Brain"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s40035-017-0076-6","article-title":"Imaging biomarkers in Parkinson\u2019s disease and Parkinsonian syndromes: Current and emerging concepts","volume":"6","author":"Saeed","year":"2017","journal-title":"Transl. Neurodegener."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s40336-014-0098-3","article-title":"Amyloid PET imaging: Applications beyond Alzheimer\u2019s disease","volume":"3","author":"Catafau","year":"2015","journal-title":"Clin. Transl. Imaging"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1002\/mds.25048","article-title":"Brain amyloid and cognition in Lewy body diseases","volume":"27","author":"Gomperts","year":"2012","journal-title":"Mov. Disord."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1001\/jamaneurol.2016.3338","article-title":"Tau Positron Emission Tomographic Imaging in the Lewy Body Diseases","volume":"73","author":"Gomperts","year":"2016","journal-title":"JAMA Neurol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1002\/ana.24825","article-title":"AV-1451 tau and \u03b2-amyloid positron emission tomography imaging in dementia with Lewy bodies","volume":"81","author":"Kantarci","year":"2017","journal-title":"Ann. Neurol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"9165458","DOI":"10.1155\/2018\/9165458","article-title":"Amyloid-Beta Radiotracer [18 F]BF-227 Does Not Bind to Cytoplasmic Glial Inclusions of Postmortem Multiple System Atrophy Brain Tissue","volume":"2018","author":"Verdurand","year":"2018","journal-title":"Contrast Media Mol. Imaging"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.ejphar.2009.06.042","article-title":"In vitro characterisation of BF227 binding to alpha-synuclein\/Lewy bodies","volume":"617","author":"Mulligan","year":"2009","journal-title":"Eur. J. Pharmacol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"6002","DOI":"10.1021\/acs.jmedchem.5b00571","article-title":"Design, Synthesis, and Characterization of 3-(Benzylidene)indolin-2-one Derivatives as Ligands for \u03b1-Synuclein Fibrils","volume":"58","author":"Chu","year":"2015","journal-title":"J. Med. Chem."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1093\/jnen\/61.11.935","article-title":"Office of Rare Diseases neuropathologic criteria for corticobasal degeneration","volume":"61","author":"Dickson","year":"2002","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.pjnns.2015.10.002","article-title":"The role of neuroimaging in the diagnosis of the atypical parkinsonian syndromes in clinical practice","volume":"49","author":"Schinwelski","year":"2015","journal-title":"Neurol. Neurochir. Pol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1136\/jnnp.2010.214890","article-title":"A new MRI rating scale for progressive supranuclear palsy and multiple system atrophy: Validity and reliability","volume":"82","author":"Rolland","year":"2011","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1007\/s00259-018-4019-y","article-title":"The role of 18F-FP-CIT PET in differentiation of progressive supranuclear palsy and frontotemporal dementia in the early stage","volume":"45","author":"Yoo","year":"2018","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0022-510X(03)00014-5","article-title":"Study of the rostral midbrain atrophy in progressive supranuclear palsy","volume":"210","author":"Kato","year":"2003","journal-title":"J. Neurol. Sci."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.arr.2015.12.009","article-title":"Molecular imaging of dopamine transporters","volume":"30","author":"Brooks","year":"2016","journal-title":"Ageing Res. Rev."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1212\/WNL.0000000000004264","article-title":"In vivo retention of 18 F-AV-1451 in corticobasal syndrome","volume":"89","author":"Smith","year":"2017","journal-title":"Neurology"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1212\/WNL.0000000000003375","article-title":"In vivo visualization of tau deposits in corticobasal syndrome by 18F-THK5351 PET","volume":"87","author":"Kikuchi","year":"2016","journal-title":"Neurology"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"145","DOI":"10.3233\/JAD-130032","article-title":"PET imaging of neuropathology in tauopathies: Progressive supranuclear palsy","volume":"36","author":"Kepe","year":"2013","journal-title":"J. Alzheimers Dis."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1002\/mds.26844","article-title":"Subcortical 18 F-AV-1451 binding patterns in progressive supranuclear palsy","volume":"32","author":"Cho","year":"2017","journal-title":"Mov. Disord."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1111\/ene.13164","article-title":"Tau imaging with [18 F]THK-5351 in progressive supranuclear palsy","volume":"24","author":"Ishiki","year":"2017","journal-title":"Eur. J. Neurol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.2967\/jnumed.116.174615","article-title":"SNMMI Procedure Standard\/EANM Practice Guideline for Amyloid PET Imaging of the Brain 1.0","volume":"57","author":"Minoshima","year":"2016","journal-title":"J. Nucl. Med."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1007\/s00259-020-04817-8","article-title":"EANM practice guideline\/SNMMI procedure standard for dopaminergic imaging in Parkinsonian syndromes 1.0","volume":"47","author":"Morbelli","year":"2020","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/21\/20\/7481\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T10:19:14Z","timestamp":1760177954000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/21\/20\/7481"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,11]]},"references-count":90,"journal-issue":{"issue":"20","published-online":{"date-parts":[[2020,10]]}},"alternative-id":["ijms21207481"],"URL":"https:\/\/doi.org\/10.3390\/ijms21207481","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,11]]}}}